Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series

Hiroyuki Kamei, Hanae Yamada, Masakazu Hatano, Manako Hanya, Shigeki Yamada, Nakao Iwata

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.

Original languageEnglish
Pages (from-to)159-163
Number of pages5
JournalClinical Psychopharmacology and Neuroscience
Volume18
Issue number1
DOIs
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series'. Together they form a unique fingerprint.

Cite this